COMPANY

OmniaMed Co., Ltd. opens up a new paradigm for the development of treatments using Nitric Oxide functionality.

OVERVIEW

Vision

Global company with competitive edge in developing Nitric Oxide drugs
Development Nitric Oxide-based BBB Transmittance Augmentation Combination and global licensing out
→ Leading the development of original treatments in the field of brain diseases that currently only relieve symptoms
Development of a first-in-class treatment based on a clear identification of Nitric Oxide-immunity systems.
→ Development of Nitric Oxide as a treatment for autoimmune diseases and cancer

What we do

OmniaMed Co., Ltd. opens up a new paradigm for the development of treatments using Nitric Oxide functionality.

As a new key factor in the conquest of brain disease / autoimmune disease / cancer, Nitric Oxide is used to develop a first-in-class cure .

A New Paradigm in Treating Diseases by Nitric Oxide Control

A number of original technologies and excellent research personnel
  • Outstanding research personnel at POSTECH
  • Source patents accumulated over many years.
  • We make the most of POSTECH's optimized research infrastructure and start-up environment.
New drug development company specialized in NO
  • Applicability of various diseases
  • Global Blue Ocean
  • World-class original NO-related research
First-in-class New Drug Development Related to NO
  • New drug development through clinical trials
  • Possible combination with various medications
  • Transferring Big Pharma Target Technology
OmniaMed Co., Ltd. is taking steps toward developing new treatments.

OmniaMed : HISTORY

2021
Mar.
Completion of Drug Evaluation R&D Center
Jan.
Establishment of Seoul Branch Office
2020
Oct.
Venture company certification (Korea Venture Capital Association)
Sep.
Signing a research service with Pohang University Laboratory
Aug.
Attracting institutional investment
Jul.
Pohang innopolis R&D Special Zone Project Selection
Apr.
Technology transfer from IBS
Apr.
Attract angel investment
Mar.
Technology transfer from POSTECH
2019
Dec.
Establishment of OmniaMed Co., Ltd. and inauguration of CEO Won Jong Kim